Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Ezgi Coban"'
Autor:
Eda Caliskan Yildirim, Elif Atag, Ezgi Coban, Olcun Umit Unal, Abdussamet Celebi, Murat Keser, Mehmet Uzun, Merve Keskinkilic, Eda Tanrikulu Simsek, Murat Sari, Tugba Yavuzsen
Publikováno v:
Breast, Vol 70, Iss , Pp 56-62 (2023)
Background: CDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on treatment response and p
Externí odkaz:
https://doaj.org/article/968ed83daa7545e0b6b5f0347defa3cf
Publikováno v:
Journal of the College of Physicians and Surgeons Pakistan. 31:792-797
OBJECTIVE To determine the diagnostic value of breast and axillary maximum standard uptake (SUVmax) values for predicting ypT0 and ypN0 separately. STUDY DESIGN A descriptive study. PLACE AND DURATION OF STUDY Department of Medical Oncology, Haydarpa
Autor:
Mesut Seker, Serkan Celik, Bala Basak Oven, Günay Gürleyik, Fugen Aker Vardar, Ali Aktekin, Ezgi Coban, Ilker Nihat Okten
Publikováno v:
Journal of Oncological Sciences. 7:7-14
Autor:
Özlem Özdemir, Baha Zengel, Yaşar Yildiz, Basak Oyan Uluç, Devrim Cabuk, Ercan Ozden, Derya Kivrak Salim, Semra Paydas, Atakan Demir, Omer Diker, Kezban Nur Pilanci, Özlem Uysal Sönmez, Sezai Vatansever, Izzet Dogan, Ahmet Gulmez, Burcu Cakar, Pinar Gursoy, Mahmut Emre Yildirim, Murat Ayhan, Nuri Karadurmus, Musa Baris Aykan, Gökcen Tugba Cevik, Teoman Sakalar, Ilhan Hacibekiroglu, Burcu Belen Gülbagci, Murat Dincer, Duygu Bayir Garbioglu, Yasemin Kemal, Erdinc Nayir, Halil Taskaynatan, Mesut Yilmaz, Okan Avci, Murat Sari, Ezgi Coban, Muhammed Mustafa Atci, Selin Aktürk Esen, Tugba Akin Telli, Fatih Karatas, Ali Inal, Hacer Demir, Nurhan Onal Kalkan, Cengiz Yilmaz, Funda Tasli, Ahmet Alacacioglu
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934c684ccacc5bd283fae448009bb29f
https://hdl.handle.net/11454/77368
https://hdl.handle.net/11454/77368
Publikováno v:
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 32(2)
To evaluate the effect of FDG-PET/CT in the radiological imaging of breast cancer (BC) patients planned for neoadjuvant treatment (NAT), on the clinical prognostic stage (CPS).A descriptive study.Haydarpasa Numune Training and Research Hospital, Ista
Autor:
Murat, Sari, Elif, Atag, Tarik, Demir, Eda Tanrikulu, Simsek, Ezgi, Coban, Makbule, Cikrikcioglu
Publikováno v:
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 32(2)
To investigate the relationship between colon cancer (CC) subtypes defined by the status of tumor-infiltrating lymphocytes (TIL) and mismatch repair (MMR) combination with clinicopathological features and survival.Observational study.Department of Me
Autor:
Sema Arici, Zuhal Gucin, Nurcan Unver, Adem Akçakaya, Zeynep Tosuner, Mustafa Hasbahceci, Ezgi Coban, Melin Özgün Geçer
Publikováno v:
Bezmiâlem Science, Vol 5, Iss 3, Pp 135-137 (2017)
Primary gastric adenosquamous carcinomas are extremely rare tumors. A gradual transition between the malignant glandular and squamous components of the tumor is seen on performing a histopathological evaluation. These tumors are known to have poorer
Autor:
Mesut Seker, Tarik Demir, Rabia Sevda Celik, H. Mehmet Turk, Tuba Baydas, Altay Aliyev, Ezgi Coban, Abdurrahim Kocyigit
Publikováno v:
Current Problems in Cancer. 44:100497
M30 and M65 levels reflect tumor cell activity in patients with epithelial cancer. Cytokeratin 18 is one of the cell skeletal elements. M30 is a apoptotic marker of cytokeratin 18. M65 levels are both an apoptosis and a necrosis marker. The aim of ou
Publikováno v:
Medicine Science | International Medical Journal. :1
Primary tumor location (PTL) is associated with very different outcomes in patients with metastatic colorectal cancer (mCRC). Clinical trials suggest that right side tumor location is an indicator of poor prognosis for patients with mCRC. The relatio
Autor:
E. Sen, Tulay Eren, Salim Basol Tekin, Ezgi Coban, Gokmen Aktas, Mustafa Karaca, Aykut Bahceci, Mustafa Benekli, B.Ö. Aliustaoglu, Melih Simsek, Serdar Turhal, Dogan Koca, Emel Yaman, Teoman Sakalar, Abdullah Sakin, Bekir Hacioglu, N.O. Kalkan, Mehmet Naci Aldemir, Mehmet Turkeli, Mehmet Bilici
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 07-11, 2016 -- Copenhagen, DENMARK
WOS: 000393912500656
…
European Soc Med Oncol
WOS: 000393912500656
…
European Soc Med Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d7a9e7ad0b9cf3e03d47474ff4eb83
https://hdl.handle.net/20.500.12395/33522
https://hdl.handle.net/20.500.12395/33522